Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation.
The mechanism of reactive hyperemia remains unknown. We hypothesized that reactive hyperemia was related to the opening of ATP-sensitive potassium channels during coronary occlusion. The resulting hyperpolarization of the smooth muscle cell plasma membrane might reduce calcium influx through voltage-dependent calcium channels and result in relaxation of smooth muscle tone and vasodilation. In eight open-chest, anesthetized dogs, 30-second coronary occlusions resulted in an average flow debt repayment of 200 +/- 41%. After low-dose (0.8 mumol/min) and high-dose (3.7 mumol/min) infusion of intracoronary glibenclamide, flow debt repayment fell to 76 +/- 14% and 50 +/- 8%, respectively (p less than 0.05 compared with control for both). The decline in flow debt repayment was due to a significant reduction both in maximum coronary conductance during reactive hyperemia and in its duration. In addition, there was a significant decline in the sensitivity of the coronary circulation to adenosine-induced vasodilation after glibenclamide. While more variable, there was no overall change in the sensitivity of the coronary vasculature to acetylcholine-induced vasodilation after glibenclamide. We conclude that reactive hyperemia is determined in a large part by the ATP-sensitive potassium channel, probably through its effect on membrane potential and voltage-sensitive calcium channels. Because reactive hyperemia was never fully abolished at the highest doses of glibenclamide tested, it is possible that additional mechanisms are involved in the genesis of this complex phenomenon.
Aversano
T
T
Johns Hopkins Medical Institutions, Baltimore, Md.
Ouyang
P
P
Silverman
H
H
D000109:Acetylcholine / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000502:physiology*; D000818:Animals; D015220:Calcium Channels / Q000187:drug effects; D003326:Coronary Circulation; D004285:Dogs; D005905:Glyburide / Q000494:pharmacology*; D006940:Hyperemia / Q000503:physiopathology*; D066298:In Vitro Techniques; D015221:Potassium Channels / Q000187:drug effects*
D015220:Calcium Channels; D015221:Potassium Channels; D000255:Adenosine Triphosphate; D000241:Adenosine; D000109:Acetylcholine; D005905:Glyburide